IPhone 16 Launch Event: Should You Buy Apple Stock Now
The highly awaited event of Apple witnessed the launch of the iPhone 16 series on September 9, 2024. It launches…
Invion (ASX:IVX): Using Photodynamic Therapy to fight cancer
Unless you’re a professional dermatologist, you may not have ever heard of Photodynamic Therapy, let alone thought of it as…
Bio Gene Technology (ASX:BGT): Commercialising a new class of insecticides
Bio Gene Technology (ASX:BGT) ASX-listed AgTech company developing two compounds – Flavocide™ and Qcide™ – as insecticides. Investors may hear…
Paradigm Biopharmaceuticals (ASX:PAR): An osteoarthritis solution that could hit the market within 3 years
If you thought the were plenty of treatments for osteoarthritis already, Paradigm Biopharmaceuticals (ASX:PAR) is a company that has something…
Cann Group (ASX:CAN): Successfully producing GMP medicinal cannabis since 2017
Cann Group (ASX:CAN) is the first company in Australia that was issued a medicinal cannabis license, granted by the Australian…
CET1 ratio: If you invest in ASX bank stocks, here’s why it is an important metric to know
In this article we look at the Common Equity Tier 1 (CET1) ratio – what it is and why it…
Star Entertainment Group (ASX:SGR): Where to now in a post-COVID world? Can it avoid a looming cash crunch?
In a July interview with the AFR, Star Entertainment Group boss Steve McCann admitted that his company’s pre-pandemic glory days…
Prescient Therapeutics (ASX:PTX): About to take the plunge into a Phase 2 trial against T-Cell Lymphoma
There’s plenty of ASX oncology biotechs conducting clinical trials, but Prescient Therapeutics (ASX:PTX) is one of the closest to commercialisation.…
5 crucial things to look for in the annual report of an ASX company that may give you an advantage over other investors
5 crucial things to look out for in the annual report of an ASX company! The ASX reporting season is…
Humm Group (ASX:HUM): Its no Big 4 Bank, but has defied the market in 2024
Humm Group (ASX:HUM) has not had the year you might expect to a financier that is not either a Big…
Here are 5 ASX stocks at 12 month highs, and whether it is time to buy
Here are 5 ASX stocks at 12 month highs! Humm Group (ASX:HUM) Humm has been through a difficult few…
Percheron Therapeutics (ASX:PER): Releasing Phase II data by the end of CY24, and successful data could lead to a major re-rate
It has been less then a year since Antisense Therapeutics changed its name to Percheron Therapeutics (ASX:PER). It is common…
Underlying v Statutory results? There’s a big difference between the 2 – here’s how to tell
When companies report results, you’ll hear underlying and statutory results. What is the difference between the two and how big…
Should I buy Woolworths or Coles shares in FY25?
Should I buy Woolworths or Coles shares? This is one of the top debates Australian investors can have. Obviously, this…
Qantas’ capex bill: The company is coping with a $12bn+ bullet for now, but will it eventually bite shareholders?
Qantas‘ capex needs are bubbling under the surface, but have not gone away. Former CEO Alan Joyce’s tenure came to…